Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications [Yahoo! Finance]
Elevai Labs, Inc. (ELAB)
Company Research
Source: Yahoo! Finance
Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced positive case study results from patients undergoing laser therapy followed by use of Elevai E-Series for applications in melasma. Elevai believes that these case studies can be the premise for future exosome research on effective melasma solutions. Melasma is a common skin condition characterized by the appearance of hyperpigmented patches and spots, typically on the face. The condition primarily affects adult women, especially those with Fitzpatrick skin types III to V. Management of melasma typically involves daily sun protection followed by a variety of treatments, including topical applications, oral therapies, chemical peels, microneedling, laser procedures, a
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- CORRECTION - Elevai Labs Inc.GlobeNewswire
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business UpdateGlobeNewswire
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]Yahoo! Finance
ELAB
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- 11/13/24 - Form 8-K
- ELAB's page on the SEC website